The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represented 4% of the insider's direct common stock holdings.

fool.com - 2026-07-13 19:28:52

PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.

zacks.com - 2026-07-10 15:16:06

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

zacks.com - 2026-07-09 14:06:06

PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-07-08 13:01:07

Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.

zacks.com - 2026-07-02 10:36:08

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

zacks.com - 2026-06-18 09:21:03

WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees.

prnewswire.com - 2026-06-17 16:30:00

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes PR Newswire

gurufocus.com - 2026-06-16 00:00:00

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity – – Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 – WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

prnewswire.com - 2026-06-15 23:14:00

– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offering to include buyback of common stock – WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

prnewswire.com - 2026-06-15 07:00:00

PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 13:12:10

PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 14:01:02

PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk.

seekingalpha.com - 2026-05-09 23:21:35

PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.

marketbeat.com - 2026-05-08 17:08:35

PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 01:51:15

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-05-07 19:30:17

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago.

zacks.com - 2026-05-07 19:01:18

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –    – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback – WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026.

prnewswire.com - 2026-05-07 16:01:00

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.

zacks.com - 2026-05-06 10:15:51

WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026 Tuesday, May 12 at 8:40 a.m.

prnewswire.com - 2026-05-04 08:00:00

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:01:34

PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript

seekingalpha.com - 2026-04-29 15:31:32

PTC Therapeutics Inc. (NASDAQ:PTCT) shares are tumbling on Wednesday, after the company reported topline results from the 24-month interim analysis of its PIVOT-HD long-term extension study.

benzinga.com - 2026-04-29 14:48:28

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile -  - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET -  WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort.

prnewswire.com - 2026-04-28 16:05:00

WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m.

prnewswire.com - 2026-04-28 09:28:00

Abacus FCF Advisors LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 75,757 shares of the biopharmaceutical company's stock, valued at approximately $5,755,000. Abacus FCF Advisors LLC owned about 0.09% of

defenseworld.net - 2026-04-26 03:14:56

WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m.

prnewswire.com - 2026-04-22 08:00:00

WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee.

prnewswire.com - 2026-04-17 16:30:00